Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

Circulation

Volumn 96, Issue 11, 1997, Pages 3860-3866

  Mascelli, Mary A ^a   Worley, Seth ^c   Veriabo, Nicholas J ^b   Lance, Ellen T ^a   Mack, Sabina ^a   Schaible, Tom ^a   Weisman, Harlan F ^a   Jordan, Robert E ^a  

^a CENTOCOR INC   (United States)

^b Chrono log Corporation   (United States)

^c Lancaster Heart Foundation   (United States)

Author keywords

Glycopreteins; Platelet aggregation inhibitors; Receptors

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030716817     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.11.3860     Document Type: Article

References (29)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or micro environment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
3. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FJ, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Calif RM, Topol EJ, for the IMPACT investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
4. Kereiakes DJ, Kleiman NS, Runyon JP, Martin LH, Hantsberger GS, McDonald S, Anders RJ. Sustained platelet GP IIb/IIIa blockade with oral Xemilofiban: pharmacodynamics with clinical outcomes in 103 patients. Circulation. 1996;94(suppl I):I-256. Abstract.
5. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley D, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin anti-platelet antibody Fab 7E3 in high risk coronary angioplasty. Circulation. 1994;90:1757-1764.
6. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton A, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or at thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cord. 1995;26:1665-1671.
7. Coller B, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Circulation. 1989;80:1766-774.
8. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in canine preparation. Circulation. 1988;77:670-677.
9. Jordan RE, Wagner CA, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab, a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIh/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, Fla: CRC Press; 1996:281-305.
10. Channing-Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16:1-20.
11. Sweeny JD, Hoernig LA, Michnik BS, Fitzpatrick JE. Whole blood aggregometry: influence of sample collection and delay in study performance on test results. J Clin Pathol. 1989;92:676-679.
12. Sweeney JD, Hoergig MS, Michnik A, Fitzpatrick JE. Whole blood platelet aggregation predicts in vitro and in vivo hemostatic function in the elderly. Arterioscler Thromb Vasc Biol. 1995;15:748-753.
13. Ingerman-Wojenski CM, Silver MJ. Quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer. Thromb Haemost. 1984;51:154-156.
14. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device of assessing platelet behavior in blood. J Pharmacol Meth. 1980;3:1350-1358.
15. Riess H, Braun G, Brehm G. Hiller E. Critical evaluation of platelet aggregation in whole blood. Am J Clin Pathol. 1986;85:50-56.
16. Coller BS, Ward P, Ceruos M, Scudder LE, Springer K, Kutok J, Prestwich GD. Thrombin receptor activating peptides: importance of the N-terminal serine and its ionization state as judged by pH dependence, nuclear magnetic resonance spectroscopy, and cleavage by aminopeptidase M. Biochemistry. 1992;31:11713-11720.
17. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-929.
18. Premarket Notification. Centocor Aggrestat, Centocor Collagen Reagent, Centocor Control Reagent. 510k-001-U. S. A. Centocor Central Documentation Center Report number 96000669. 1995:1.
19. Wagner, CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIh/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996;88:907-914.
20. Thomson C, Forbes CD, Prentice CBM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med. 1973;45:485-494.
21. Berglund U, Wallentin L. Influence on platelet function by heparin in men with unstable coronary artery disease. Thromb Haemost. 1991;66:648-651.
22. Konstantopoulos K, Kamat SG, Schafer AI, Bãnez EI, Jordan R, Kleiman NS, Hellums JD. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation. 1995;91:1427-1431.
23. Holmsen H. Platelet secretion and energy metabolism. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia, Pa: JB Lipincott Co; 1994:524-556.
24. Blackwell GJ, Flower RJ, Russell-Smith N, Salmon JA, Thorogood PB, Vane JR. Prostacyclin is produced in whole blood. Br J Pharmacol. 1978;64:436.
25. Benveniste J, Cochrane CG, Henson PM. Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils and platelet-activating factor. J Exp Med. 1922;136:1356-1377.
26. Benveniste J, Jouvin E, Pirotzky E. Platelet activating factor (PAF-acether): molecular aspects of its release and pharmacological actions. Int Arch Allergy Immunol. 1981;66(suppl 1):121-126.
27. 2), by human erythrocytes. Br J Haematol. 1983;54:43-52.
28. Gaarder A, Jonson J, Leland S. Adenosine diphosphate in red cells as a factor in adhesiveness of human blood platelets. Nature. 1961;192:531-532.
29. Karpatkin S, Charmatz A. Heterogeneity of human platelets, 1: metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest. 1969;48:1073-1087.